103 related articles for article (PubMed ID: 20299330)
1. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Webb IG; Nishino Y; Clark JE; Murdoch C; Walker SJ; Makowski MR; Botnar RM; Redwood SR; Shah AM; Marber MS
Cardiovasc Res; 2010 Aug; 87(3):494-503. PubMed ID: 20299330
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart.
Umbarkar P; Tousif S; Singh AP; Anderson JC; Zhang Q; Tallquist MD; Woodgett J; Lal H
Circ Res; 2022 Sep; 131(7):620-636. PubMed ID: 36052698
[TBL] [Abstract][Full Text] [Related]
3. Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis.
Umbarkar P; Ejantkar S; Ruiz Ramirez SY; Toro Cora A; Zhang Q; Tousif S; Lal H
Basic Res Cardiol; 2023 Sep; 118(1):35. PubMed ID: 37656238
[TBL] [Abstract][Full Text] [Related]
4. DYRK2 negatively regulates cardiomyocyte growth by mediating repressor function of GSK-3β on eIF2Bε.
Weiss CS; Ochs MM; Hagenmueller M; Streit MR; Malekar P; Riffel JH; Buss SJ; Weiss KH; Sadoshima J; Katus HA; Hardt SE
PLoS One; 2013; 8(9):e70848. PubMed ID: 24023715
[TBL] [Abstract][Full Text] [Related]
5. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.
Antos CL; McKinsey TA; Frey N; Kutschke W; McAnally J; Shelton JM; Richardson JA; Hill JA; Olson EN
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):907-12. PubMed ID: 11782539
[TBL] [Abstract][Full Text] [Related]
6. Immune cell β
Tanner MA; Maitz CA; Grisanti LA
Am J Physiol Heart Circ Physiol; 2021 Oct; 321(4):H633-H649. PubMed ID: 34415184
[TBL] [Abstract][Full Text] [Related]
7. Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and Lipotoxic Cardiomyopathy.
Nakamura M; Liu T; Husain S; Zhai P; Warren JS; Hsu CP; Matsuda T; Phiel CJ; Cox JE; Tian B; Li H; Sadoshima J
Cell Metab; 2019 May; 29(5):1119-1134.e12. PubMed ID: 30745182
[TBL] [Abstract][Full Text] [Related]
8. Overexpressing of the GIPC1 protects against pathological cardiac remodelling.
Sun X; Han Y; Yu Y; Chen Y; Dong C; Lv Y; Qu H; Fan Z; Yu Y; Sang Y; Tang W; Liu Y; Ju J; Zhao D; Bai Y
Eur J Pharmacol; 2024 May; 971():176488. PubMed ID: 38458410
[TBL] [Abstract][Full Text] [Related]
9. AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to β-adrenergic-induced cardiac hypertrophy.
Spindler MJ; Burmeister BT; Huang Y; Hsiao EC; Salomonis N; Scott MJ; Srivastava D; Carnegie GK; Conklin BR
PLoS One; 2013; 8(4):e62705. PubMed ID: 23658642
[TBL] [Abstract][Full Text] [Related]
10. MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo.
Xu Y; Liang C; Luo Y; Zhang T
J Cell Mol Med; 2021 Jan; 25(2):1100-1115. PubMed ID: 33295096
[TBL] [Abstract][Full Text] [Related]
11. p38γ and p38δ regulate postnatal cardiac metabolism through glycogen synthase 1.
Santamans AM; Montalvo-Romeral V; Mora A; Lopez JA; González-Romero F; Jimenez-Blasco D; Rodríguez E; Pintor-Chocano A; Casanueva-Benítez C; Acín-Pérez R; Leiva-Vega L; Duran J; Guinovart JJ; Jiménez-Borreguero J; Enríquez JA; Villlalba-Orero M; Bolaños JP; Aspichueta P; Vázquez J; González-Terán B; Sabio G
PLoS Biol; 2021 Nov; 19(11):e3001447. PubMed ID: 34758018
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D2 is a critical mediator of exercise-induced cardiac hypertrophy.
Luckey SW; Haines CD; Konhilas JP; Luczak ED; Messmer-Kratzsch A; Leinwand LA
Exp Biol Med (Maywood); 2017 Dec; 242(18):1820-1830. PubMed ID: 28901173
[TBL] [Abstract][Full Text] [Related]
13. Exercise training can prevent cardiac hypertrophy induced by sympathetic hyperactivity with modulation of kallikrein-kinin pathway and angiogenesis.
Silva JA; Santana ET; Manchini MT; Antônio EL; Bocalini DS; Krieger JE; Tucci PJ; Serra AJ
PLoS One; 2014; 9(3):e91017. PubMed ID: 24614810
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of alcohol dehydrogenase aggravate ethanol-evoked cardiac remodeling and contractile anomalies through FKBP5-yap-mediated regulation of ferroptosis and ER stress.
Lu Q; Qin X; Chen C; Yu W; Lin J; Liu X; Guo R; Reiter RJ; Ashrafizadeh M; Yuan M; Ren J
Life Sci; 2024 Apr; 343():122508. PubMed ID: 38382873
[TBL] [Abstract][Full Text] [Related]
15. Lack of Matrilin-2 favors liver tumor development via Erk1/2 and GSK-3β pathways in vivo.
Fullár A; Baghy K; Deák F; Péterfia B; Zsák Y; Tátrai P; Schaff Z; Dudás J; Kiss I; Kovalszky I
PLoS One; 2014; 9(4):e93469. PubMed ID: 24691449
[TBL] [Abstract][Full Text] [Related]
16. Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease.
Baccam GC; Xie J; Jin X; Park H; Wang B; Husson H; Ibraghimov-Beskrovnaya O; Huang CL
Sci Rep; 2022 Jun; 12(1):9340. PubMed ID: 35660779
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional changes during isoproterenol-induced cardiac fibrosis in mice.
Nanda D; Pant P; Machha P; Sowpati DT; Kumarswamy R
Front Mol Biosci; 2023; 10():1263913. PubMed ID: 38178867
[No Abstract] [Full Text] [Related]
18. Recurrent Adrenergic Stress Provokes Persistent Myocarditis in PD-1-Deficient Mice.
Hayashi T; Lim KRQ; Kovacs A; Mann DL
JACC Basic Transl Sci; 2023 Dec; 8(12):1503-1517. PubMed ID: 38205352
[TBL] [Abstract][Full Text] [Related]
19. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy.
Molkentin JD; Lu JR; Antos CL; Markham B; Richardson J; Robbins J; Grant SR; Olson EN
Cell; 1998 Apr; 93(2):215-28. PubMed ID: 9568714
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cardiac hypertrophy in mice by calcineurin inhibition.
Sussman MA; Lim HW; Gude N; Taigen T; Olson EN; Robbins J; Colbert MC; Gualberto A; Wieczorek DF; Molkentin JD
Science; 1998 Sep; 281(5383):1690-3. PubMed ID: 9733519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
